β-Caryophyllene (BCP)—a selective CB2 agonist—ameliorates DNCB-induced AD-like dermatitis and downregulates keratinocyte TSLP/EGR1, supporting antipruritic and anti-inflammatory actions consistent with our cytokine trends [29]. The gene discussed is EGR1; the disease is skin disorder.